ODAIA Appoints Former WebMD Exec Dr. Eric Trépanier as Chief Commercial Officer
25+ year industry vet will supercharge ODAIA’s marketing, sales development, customer success, and commercial operations
The future of pharma analytics is AI, and ODAIA is a true trailblazer in connecting pharmaceutical commercial teams to optimal healthcare providers in a fraction of the time
ODAIA, the company empowering pharma’s next generation of engagement with healthcare professionals, today announced the addition of Dr. Eric Trépanier (Pharm.D, CFA) as the company’s new Chief Commercial Officer. This new position comes at an important inflection point for ODAIA, having ended 2022 with 800% year over year growth. With over 25 years of industry experience, Trépanier will drive sales of ODAIA’s MAPTUAL Sphere and MAPTUAL Field products, which aim to expand and deepen relationships between physicians and the commercial teams and sales reps at pharma companies.
“The future of pharma analytics is AI, and ODAIA is a true trailblazer in connecting pharmaceutical commercial teams to optimal healthcare providers in a fraction of the time,” said Eric Trépanier. “Through predictive analytics and commercial insights, ODAIA’s MAPTUAL offering connects pharma teams with HCPs better, faster, and more effectively, so that patients are getting the treatment they need. This will transform the industry and patient outcomes for the better, and I am excited to help drive visibility and growth as the company continues to expand.”
Trépanier joins ODAIA from Medicx Health, where he spearheaded a cultural transformation that stabilized revenue, returned the company to strong double-digit growth, and increased diversification as EVP and General Manager. Prior to Medicx, Trépanier served as SVP of Marketing Sciences on WebMD’s leadership team, which produced double-digit revenue and profit growth from 2013-2016 and sold WebMD to KKR’s Internet Brands at an all-time high share price.
“As we continue to power meaningful connections between pharma companies and healthcare providers, Dr. Trépanier will unlock the full potential of our offerings,” said Philip Poulidis, CEO and co-founder of ODAIA. “His two-plus decades of experience in pharma will ensure that healthcare providers are getting timely information about beneficial therapies for their patients.”
ODAIA’s predictive analytics SaaS products leverage prescriber transactions, anonymized patient health claims data, population demographic and socioeconomic data, anonymized lab data, and more to supercharge pharma sales reps and pharma commercial teams, who both aim to reach healthcare providers (HCPs) to educate about new therapeutic options and standards of care.
To improve your sales and connect with HCPs faster and more effectively, learn more about ODAIA by visiting: https://www.odaia.ai/
To connect with the ODAIA team during the JP Morgan Healthcare Conference in San Francisco from January 9-12, 2023, please email: jpmhc@odaia.ai
About ODAIA
ODAIA is a leader in life sciences predictive analytics and commercial insights. ODAIA’s AI-powered platform, MAPTUAL, leverages a proprietary analytics engine to help pharma companies prospect, qualify and engage their customers, which helps reduce patients’ time to therapy. The platform has seen strong traction and demonstrated success with innovative Fortune 500 biopharma companies. To learn more, visit www.odaia.ai or follow on the company social at @odaiaAI.
( Press Release Image: https://photos.webwire.com/prmedia/42381/298933/298933-1.jpg )
WebWireID298933
- Contact Information
- Molly O’Connor
- PR for ODAIA
- VSC for ODAIA
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.